Zealthy Tirzepatide: Dual Agonist, Compounding, Cost

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

From the PlexusDx Education Hub, our evidence-based resource on GLP-1 therapy, weight management, and the genetics that inform metabolic care. Browse all Peptides & GLP-1 education

Independent editorial review. PlexusDx has no commercial relationship with Zealthy or its parent company, and no affiliate links or compensation are involved.

Tirzepatide is the newer, structurally distinct entrant in the GLP-1 conversation, and this review keeps the focus there: what the molecule is, and how a telehealth program such as Zealthy handles it. Because tirzepatide is engineered differently from semaglutide, the compound deserves its own examination before the program around it. As of April 2026.

Tirzepatide as a dual GIP/GLP-1 agonist

Tirzepatide is a GIP/GLP-1 dual agonist — it engages two incretin receptors rather than one. Like other agents in the family, it slows gastric emptying, tempers post-meal glucose, and heightens satiety, but the added GIP receptor activity is what structurally separates it from GLP-1-selective molecules such as semaglutide, liraglutide, and dulaglutide. Retatrutide, a triple agonist, remains investigational and not FDA-approved.

Branded tirzepatide versus compounded tirzepatide

Tirzepatide reaches patients two ways in telehealth. As a branded, FDA-approved product it is dispensed from a retail pharmacy against a prescription; the brand names are Mounjaro (type 2 diabetes) and Zepbound (chronic weight management, plus a 2024 sleep apnea indication). Compounded tirzepatide is prepared by a 503A compounding pharmacy for an individual prescription — a distinct regulatory pathway from FDA-approved manufacturing.

How Zealthy dispenses tirzepatide

The dispensing flow mirrors the broader model: an intake capturing weight, history, and medications; a licensed clinician's review and, where appropriate, a prescription; routing to a retail pharmacy for a brand product or a 503A pharmacy for a compounded preparation; and follow-up for titration and side-effect support. Current program structure and pricing are posted on Zealthy's official website.

Trial evidence for tirzepatide

Tirzepatide's record comes from its own programs. SURMOUNT studied it for weight management (published in The New England Journal of Medicine, 2022), and SURMOUNT-OSA addressed obstructive sleep apnea (NEJM, 2024); the SURPASS program covered type 2 diabetes. Populations and endpoints differ across these trials, and individual outcomes vary — the data reflects trial averages rather than a personal forecast.

Tirzepatide cost across the market

What tirzepatide costs depends on brand versus compounded dispensing and subscription tier. Typical monthly totals across the telehealth GLP-1 market as of April 2026 land between roughly $200 and $700+, with wide variance; confirm current figures on the brand's own site. By comparison, PlexusDx lists its Tirzepatide Injection at $289 per month — its own transparent price, stated up front rather than a competitor estimate.

The genetics beneath a tirzepatide response

Tirzepatide acts on a metabolic system that genetics has already shaped. GLP1R encodes one of the receptors it targets; FTO influences appetite and adiposity set-point; MC4R anchors energy balance; and TCF7L2 links to glucose homeostasis and GLP-1 secretion. These pathway-level variants do not predict tirzepatide response, but they describe the biology the compound engages.

PlexusDx offers tirzepatide through its Weight Management Protocols as Tirzepatide Injection and Tirzepatide Oral. Before starting, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including FTO, GLP1R, MC4R, and TCF7L2 — adding the upstream context a prescription alone leaves out.

Not affiliated: PlexusDx has no partnership or commercial tie to Zealthy; this review is editorial only.

Related reading on PlexusDx: Medvi Zepbound, Mochi Zepbound, Noom Zepbound, and AgelessRx Zepbound.

Editorial note: educational only. PlexusDx is not affiliated with Zealthy and offers semaglutide and tirzepatide through its own protocols. The Precision Peptide Genetic Test analyzes how genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified provider before beginning any protocol.

Begin with the biology: take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

What makes tirzepatide different from semaglutide?

Tirzepatide is a GIP/GLP-1 dual agonist, engaging two incretin receptors, while semaglutide is GLP-1-selective. Both slow gastric emptying and increase satiety, but the added GIP activity is the structural difference. This is why the two are dosed and studied on separate tracks rather than treated as equivalents.

Does Zealthy dispense compounded or brand tirzepatide?

Depending on the program and tier, tirzepatide may be dispensed as FDA-approved brand product (Mounjaro or Zepbound) through a retail pharmacy or as compounded tirzepatide through a 503A pharmacy. Which pathway applies is published on the brand's own site and determines what a patient receives.

Is compounded tirzepatide the same as Zepbound?

No. Zepbound is an FDA-approved brand product. Compounded tirzepatide is prepared by a 503A pharmacy for an individual prescription under a separate regulatory pathway. They share the same active compound category but differ in how they are produced and regulated, which is worth confirming before purchase.

Can a genetic test predict tirzepatide results?

No. The Precision Peptide Genetic Test does not predict response to tirzepatide or any medication. It maps pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe baseline metabolic biology — context for a provider conversation, not a forecast of individual outcomes.

More explainers await at the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.